Not a good buy right now: the trend is firmly bearish (SMA_200 > SMA_20 > SMA_5) and MACD is negative and worsening.
Oversold RSI (19.35) can trigger a short-lived bounce, but with no catalysts and heavy hedge-fund selling, odds favor continued pressure rather than a durable reversal.
Price is hovering just above near-term support (S1=0.177). An impatient entry here is effectively a gamble on a technical bounce, not a trend-following buy.
Key levels: Pivot=0.271 (overhead), resistance R1=0.365, R2=0.422; these are far above current price and represent heavy overhead supply.
Pattern-based forward look (from similar candlesticks): ~50% chance of -0.45% next day; +1.64% next week; +5.12% next month (small expected upside and very uncertain, given volatility).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning is extremely call-skewed: call OI 12,869 vs put OI 21 (put/call ~0) → sentiment/positioning leans bullish/speculative, but can also reflect low-priced “lottery ticket” calls.
Volume is also call-dominant: call vol 1,469 vs put vol 3 (put/call ~0).
Volatility is very high: HV ~181.56, IV30 ~236.72 → market is pricing large moves; this typically increases risk of whipsaws.
IV is elevated but not at extremes by its own history (IV percentile 28.8; IV rank 20.71) → not screaming “peak panic,” despite the very high absolute IV.
Today’s option activity is unusually high vs its 30D average (volume vs avg ~359.9; OI vs avg ~151.03) → heightened speculative interest.
Technical Summary
Sell
8
Buy
3
Positive Catalysts
holds.
Neutral/Negative Catalysts
with multiple resistance levels overhead → rallies may be sold into.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (down -100% YoY) → top-line traction is effectively absent in the reported quarter.
Net income: -15.778M (improved ~49.05% YoY) → losses narrowed, but the company is still meaningfully unprofitable.
EPS: -0.27 (improved ~22.73% YoY) → per-share loss improved, but still negative.
Gross margin: 0 (down -100% YoY) → consistent with zero revenue; fundamentals are not currently supporting a bullish thesis.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating trend or price target change data was provided, so sentiment from Wall Street analysts cannot be verified here.
Practical read given available data: without revenue in the latest quarter and with heavy hedge-fund selling, the “pro” case is weak; any bullish view would likely rely on pipeline/strategic developments not included in the dataset.
Politicians / influential figures: no recent congress trading data available in the last 90 days.
Wall Street analysts forecast BCAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAB is 10 USD with a low forecast of 10 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BCAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAB is 10 USD with a low forecast of 10 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.190
Low
10
Averages
10
High
10
Current: 0.190
Low
10
Averages
10
High
10
Citizens JMP
Reni Benjamin
Outperform -> Market Perform
downgrade
$NULL
AI Analysis
2025-08-13
Reason
Citizens JMP
Reni Benjamin
Price Target
$NULL
AI Analysis
2025-08-13
downgrade
Outperform -> Market Perform
Reason
Citizens JMP analyst Reni Benjamin downgraded BioAtla to Market Perform from Outperform without a price target following the Q2 report. The firm views the shares as fairly valued given expecatatations for no revenue or earnings in the near future. BioAtla is facing an evolving landscape and uncertainty regarding a potential partnership, the analyst tells investors in a research note. With a partnership, Citizens views the company's current cash position as insufficient to sustain operations.
